期刊文献+

达沙替尼片在中国健康人体内的药动学 被引量:5

Pharmacokinetics of dasatinib tablets in Chinese healthy volunteers
原文传递
导出
摘要 目的:建立人血浆中达沙替尼浓度的液-质联用(LC-MS/MS)测定法,研究达沙替尼片在中国健康人体内的药动学。方法:24例男性健康受试者单剂量空腹口服100 mg达沙替尼片,0~48 h间隔采集肘静脉血,分离血浆测定达沙替尼血药浓度,采用DAS 2.0软件计算药动学参数。结果:达沙替尼的主要药动学参数:C max为(204.2±60.6)ng·mL-1,T max为(0.55±0.13)h,t1/2为(5.5±1.4)h,AUC0~48 h为(668±207)ng·h·mL-1,AUC0~∞为(684±208)ng·h·mL-1,CL为(164.3±66.2)L·h-1,V为(1 341±1 022)L。结论:建立的LC-MS/MS测定法专属、灵敏,满足达沙替尼片药动学研究的要求。测得达沙替尼片在中国人体内的吸收明显高于美国人。 Objective: To establish an LC-MS /MS method for the determination of plasma concentration of dasatinib,and to study the pharmacokinetics of dasatinib tablets in healthy male Chinese volunteers.Methods: Twenty-four volunteers were given a single oral dose of 100 mg dasatinib tablets(Jiangsu Chia-tai Tianqing Pharmaceutical Co.Ltd.).Venous blood samples were withdrawn at designed intervals between 0 and 48 h.The plasma concentrations of dasatinib were determined by the validated LC-MS / MS method and the pharmacokinetic parameters were calculated by DAS 2.0 software.Results: The main pharmacokinetic parameters after a single oral dose of 100 mg dasatinib tablets were as follows: C max was(204.2 ± 60.6) ng·mL-1,T max was(0.55 ± 0.13) h,t 1 /2 was(5.5 ±1.4) h,AUC 0 ~ 48 h was(668 ± 207) h·ng·mL-1,AUC 0 ~ ∞ was(684 ± 208) ng·h·mL-1,CL was(164.3 ±66.2) L·h-1and V was(1 341 ±1 022) L.Conclusion: The LC-MS/MS method has been proved to be specific and sensitive.The established method is successfully applied to the pharmacokinetics of dasatinib tablets in healthy male Chinese volunteers.The absorption in the Chinese volunteers is significantly higher than that of American volunteers.
出处 《中国新药杂志》 CAS CSCD 北大核心 2013年第17期2060-2064,共5页 Chinese Journal of New Drugs
关键词 达沙替尼 药动学 液相色谱-串联质谱法 dasatinib tablets pharmacokinetics LC-MS/MS
  • 相关文献

参考文献14

  • 1STEIN B,SMITH BD. Treatment options for patients with chron-ic myeloid leukemia who are resistant to or unable to tolerate ima-tinib[J]. Clin Ther, 2010, 32(5) :804 -820.
  • 2KANTARJIAN H, SHAH NP, HOCHHAUS A, et al. Dasatinibversus imatinib in newly diagnosed <;hronic-phase chronic myeloidleukemia[J]. N Engl J Med, 2010,362(24):2260 -2270.
  • 3HOCHHAUS A,BACCARANI M, DEININGER M, et al. Da-satinib induces durable cytogenetic responses in patients withchronic myelogenous leukemia in chronic phase with resistance orintolerance to imtinib [ J ]. Leukemia,2008,22 ( 6 ) : 1200 -1206.
  • 4CHRISTOPHER LJ, CUI D, WU C , et al. Metabolism and dis-position of dasatinib after oral administration to humans [ J ].Drug Metab Dispos , 2008,36(7) :1357 - 1364.
  • 5US Food and Drug Administration. SPRYCEL? ( dasatinib) Tab-let for Oral Use. 2006 [ EB/OL]. (2010 -10). http ://www. ac-cessdata. fda. gov/drugsatfda _ docs/label/2010/021986s7s81bl.pdf.
  • 6FURLONG MT,AGRAWAL S, HAWTHOME D, et al. A vali-dated LC-MS/MS assay for the simultaneous determination of theanti-leukemic agent dasatinib and two pharmacologically activemetabolites in human plasma : Application to a clinical pharmaco-kinetic study[ J] . J Pharm Biomed Anal, 2012 , 58 : 130 ~ 135.
  • 7ROCHE S, MCMAHON G, CLYNES M, O'CONNOR R. Devel-opment of a high-performance liquid chromatographic-mass spec-trometric method for the determination of cellular levels of thetyrosine kinase inhibitors lapatinib and dasatinib [ J ]. J Chroma-togr B Analyt Technol Biomed Life Sci, 2009,877 (31 ) :3982 -3990.
  • 8DE FRANCIA S, D'AVOLIO A, DE MARTINO F, et al. NewHPLC-MS method for the simultaneous quantification of the an-tileukemia drugs imatinib, dasatinib, and nilotinib in humanplasma [ J ]. J Chromatogr B Analyt Technol Biomed. Life Sci,2009, 877(18 - 19) :1721 - 1726.
  • 9Center for Drug Evaluation and Research [ EB/OL ] . ( 2006 -09). http://www. accessdata. fda. gov/drugsatfda _ ciocs/nda/2006/021986s000_SprycelClinPharmR. pdf.
  • 10田园.达沙替尼治疗伊马替尼耐药的慢性粒细胞白血病的研究进展[J].医学信息(中旬刊),2010,5(8):2292-2293. 被引量:6

二级参考文献1

共引文献5

同被引文献21

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部